BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...
FierceBiotech14h
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
pharmaphorum15h
Obesity drug developer BioAge raises $198m in IPO
BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...
BioAge seeks nearly $200 million in initial public offering
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
FierceBiotech1d
BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...
BioPharma Dive22h
BioAge prices $198M IPO, validating pivot to obesity drug research
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
ENDPOINTS NEWS16h
Next-gen obe­si­ty biotech BioAge Labs to raise $198M in IPO
A California biotech that began as an anti-aging company, then licensed an Amgen heart failure drug for $1 million upfront ...
BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
IPO Roundup: Guardian Pharmacy Services, BKV Corp and more
The U.S. IPO market looks stable this week, with a few new companies aiming to raise capital, as the Federal Reserve reduced ...